BPC-157

BPC-157 is a synthetic peptide of 15 amino acids. The name stands for "body protection compound". Over three decades, animal studies have credited it with healing tendons, muscles, bones, nerves, the gut and the cornea[1]. Among athletes it is known as the "Wolverine peptide", after the comic-book character who heals from any wound[2], and it is widely sold online[3].

The gap between reputation and evidence is unusually wide. A 2025 systematic review found 36 relevant studies, and 35 of them were done in animals[4]. Only three small studies in people have been published[1]. This page sets out what is known about the peptide, what has actually been tested, and why regulators and anti-doping authorities restrict it.

Where it comes from

BPC-157 was described in 1993 by Predrag Sikirić and colleagues at the University of Zagreb, who reported it as part of a larger compound isolated from human gastric juice[3][1]. The peptide used in experiments is synthetic[5][6]. Its sequence shows no similarity to known gut peptides[6][3], and the larger protein it is said to belong to has not been characterised in the reviews on this page.

Marketing texts sometimes describe BPC-157 as a fragment of PDGF-BB, a growth factor involved in wound healing. The sequence does not support this. In the wound-healing experiments cited by the Zagreb group, PDGF-BB was used as a comparator, not as the source of the sequence: in diabetic mice, the two had a similar effect on granulation tissue[6].

Most of the research has come from one place. A 2024 review by the Zagreb group, with 22 authors, cites more than 130 studies of the peptide published over 30 years[5], and much of the published work comes from this group[3].

What the sequence tells us

BPC-157 is a small, unmodified linear peptide. It has no disulfide bonds, no lipid chain and no amino acids outside the standard twenty, so it is easy to make by solid-phase synthesis[5]. It carries a net negative charge at neutral pH, because three acidic residues outweigh a single lysine.

The most unusual claim about it concerns stability. The Zagreb group reports that BPC-157 remains intact in human gastric juice for at least 24 hours, whereas the growth factors EGF and TGF-α are destroyed within 15 minutes, and it explains its effects after oral dosing in this way[6]. Prolines make peptide chains rigid and hard for many proteases to cut. A commentary on the Zagreb review asked whether the run of three prolines is what protects the peptide, and noted that this has not been tested[5].

Stability in the stomach is not the same as a long life in the body. In rats and dogs given labelled BPC-157 by injection, the half-life was under 30 minutes, and the peptide was cleared by the kidneys and liver[2][4]. For people there are almost no data on blood levels: a 2002 pharmacokinetic study is described in the literature only briefly[3], and the two-person infusion study measured only routine blood tests and vital signs, not the peptide itself[2]. The Zagreb group also cites an unpublished 1996 report giving a half-life of 66 to 69 hours after oral dosing of radiolabelled peptide in rats[6]. Radioactivity measurements cannot tell the intact peptide from its breakdown products, so the two figures do not necessarily contradict each other, but the unpublished one cannot be checked.

Animal studies

In rats, BPC-157 has been reported to speed the healing of cut tendons, ligaments and muscles, to improve bone healing and to protect the stomach and intestine against alcohol, anti-inflammatory drugs and other injuries[1][6]. Proposed mechanisms include the formation of new blood vessels through the VEGF receptor 2 and nitric oxide, activation of the ERK1/2 signalling pathway, and increased expression of the growth hormone receptor in tendon cells[1]. Effects have been reported at doses from micrograms down to nanograms per kilogram[6].

The breadth of these claims is itself a warning sign. The 2024 Zagreb review lists benefits for the gut, liver, brain, heart, blood vessels, lungs and kidneys[6]. One commentator wrote that it "almost seems too good to be true"[5]. A 2025 review from the University of Utah noted that all published studies report positive effects, which suggests publication bias, and that the robustness and reproducibility of the results are open questions[1]. A systematic review rated the evidence as level IV and V, the lowest levels[4].

Studies in people

Three small studies in people have been published. All three come from the same physician, Edwin Lee, and appeared in the same journal, Alternative Therapies in Health and Medicine[1].

Knee study as summarised by its author[2] and by Vasireddi et al. (2025)[4]; cystitis study from Lee et al. (2024)[7]; infusion study from Lee and Burgess (2025)[2].

None of these studies had a control group, so it cannot be known how much of the improvement was due to the peptide. The knee study was retrospective, with patients contacted months later to report on their pain[1]. In the cystitis study, the outcome was the patients' own rating of their symptoms[7]. The infusion study enrolled two people who had already received intravenous BPC-157 before[2]. The two later studies were done at private clinics, with peptide from compounding pharmacies the authors did not name[2][7]. In both of the later papers, the author argues that the FDA should allow compounding pharmacies to produce BPC-157[2][7].

A systematic review published in October 2026 assessed all three studies with a standard tool for uncontrolled before-and-after studies. It judged their methodological quality as poor and rated the overall certainty of the human evidence as very low. Its authors concluded that BPC-157 should not be used in people outside regulated, high-quality clinical trials[8].

Two other human studies are mentioned in the literature but cannot be assessed. A phase I trial in 42 healthy volunteers began in 2015, but the researchers cancelled the submission of its results in 2016[3]. The Zagreb group refers to a phase II trial in ulcerative colitis with no side effects[6]. When the FDA reviewed BPC-157 for this condition in 2026, the only report it found was a conference abstract of a small trial of BPC-157 enemas in 53 patients, which it judged inadequate to show effectiveness[9].

Safety

In animal toxicology studies no lethal dose was found, and no toxic effects on organs, development or genes were reported[1][3]. In people, safety data are limited to the three small, uncontrolled studies, with 30 participants in total and short, non-standardised monitoring for adverse events. No adverse events were reported in them, but they cannot establish the risks of repeated or long-term use[1][4][8].

Reviewers have raised possible risks based on how the peptide is thought to act. If BPC-157 promotes the growth of blood vessels, it could in principle also support the growth of tumours. Strong stimulation of nitric oxide production could have other unwanted effects[1][3]. These are hypotheses, not observed effects. The animal studies even report anti-tumour effects[1]. But one review concluded that "there is no convincing certainty that BPC 157 is harmless"[3].

The more immediate risk lies in the product. BPC-157 is sold on websites as a "research chemical", without regulatory control over its content, purity or sterility[1][4]. The FDA lists possible immune reactions to injected peptide and impurities from peptide synthesis among its concerns[10].

Legal status

BPC-157 is not approved as a medicine by the FDA or any other regulator[3]. In the United States it was nominated for use by compounding pharmacies, and in 2023 the FDA placed it in the category of substances that may present significant safety risks[1][4]. After the nominations were withdrawn, it was moved off that list; the FDA page, last updated in April 2026, still states that BPC-157 "may pose risk for immunogenicity for certain routes of administration", may have complexities with peptide-related impurities, and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans"[10].

The question was reopened in 2026. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee considered whether BPC-157 and its acetate salt should be added to the list of substances that pharmacies may use for compounding, for the treatment of ulcerative colitis[11]. FDA staff recommended against it: their briefing document described the substance as not well characterised, found no adequate evidence of effectiveness and insufficient clinical safety information, and warned of a possible risk of immune reactions[9]. The committee nevertheless voted to recommend inclusion[12]. The recommendation is advisory: it does not make BPC-157 an approved medicine or establish its safety and effectiveness, and the final decision rests with the FDA.

In sport, the World Anti-Doping Agency has prohibited BPC-157 since 2022. Its 2026 Prohibited List names it explicitly as an example of class S0, substances with no approval for human therapeutic use, which are banned in and out of competition[13][1].

BPC-157 may yet prove useful. The animal data are extensive enough that independent reviewers call for proper clinical trials[1][4]. Until such trials are done, its benefits in people are a hypothesis, and its safety in people is unknown.

References

1. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine 18:611–619. DOI: 10.1007/s12178-025-09990-7
2. Lee E, Burgess K (2025). Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine 31(5):20–24.
3. Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. Pharmaceuticals 18:185. DOI: 10.3390/ph18020185
4. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal 21:485–495. DOI: 10.1177/15563316251355551
5. Whitehouse M (2025). Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant and is believed to protect the gastro-intestinal tract (GIT). Inflammopharmacology 33:4879–4881. DOI: 10.1007/s10787-025-01882-z
6. Sikirić P, Sever M, Krezić I, Vraneš H, Kalogjera L, Smoday IM, Vuković V, Oroz K, Čorić L, Škoro M, Kavelj I, Zubčić S, Sikirić S, Beketić Orešković L, Orešković I, Blagaić V, Brčić K, Štrbe S, Starešinić M, Boban Blagaić A, Škrtić A, Seiwerth S (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology 32:3119–3161. DOI: 10.1007/s10787-024-01499-8
7. Lee E, Walker C, Ayadi B (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Alternative Therapies in Health and Medicine 30(10):12–17.
8. Poolton JT, Minett J, Kazmi A (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica 92(3). DOI: 10.52628/92.3.15837
9. U.S. Food and Drug Administration (2026). BPC-157 (free base) and BPC-157 acetate: briefing document for the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026. fda.gov (PDF)
10. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. fda.gov
11. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
12. The BMJ (2026). News report on the FDA Pharmacy Compounding Advisory Committee vote on BPC-157, 28 July 2026. BMJ 394. bmj.com
13. World Anti-Doping Agency (2025). The 2026 Prohibited List, International Standard. wada-ama.org